

Chicago Specials

Fall Group Meeting

OCTOBER 8 - 10, 2026



Melanoma Committee

Melanoma Committee

Leadership

Chair: Sapna P. Patel, MD
 Vice-Chair: Roger S. Lo, MD, PhD
 Executive Officer: Hagen Kennecke, MD
 Statisticians: Michael Wu, PhD
 Megan Othus, PhD
 James Moon, MS
 Gabby Lopez, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: William Carson, MD
 Radiation Oncology: TBD
 Surgery: John Robert Hyngstrom, MD
 Dermatology: TBD
 Imaging: TBD
 Medical Oncology: TBD
 Pathology: TBD
 Non-Melanoma Skin Cancer: Nikhil I. Khushalani, MD
 Early Therapeutics: TBD
 SWOG's ECOG Liaisons: Sunandana Chandra, MD
 G. Paul Wright, Jr., MD
 ECOG's SWOG Liaisons: David H. Lawson, MD
 Michael Lowe, MD

Designates

Adolescent & Young Adults: Leah Winer, MD
 Cancer Control: Sancy Leachman, MD, PhD (Prevention)
 Data Coordinator: Michele Counts, BS
 Tonya Johnson, BS
 Oncology Research Professionals: Barbara J. Lomasney, RN, OCN
 Kathryn Allen, BA, CCRP
 Patient Advocate: Sara Selig, MD
 Pharmaceutical Science: Sun "Coco" Yang, PharmD, PhD
 Stephanie Elise Trexler, PharmD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, October 10, 2026 11:30 a.m. - 1:30 p.m.
 Room: Regency D (Ballroom Level)

Agenda

11:30 - 11:45 am **Welcome & Updates** - Sapna Patel, MD

11:45 - 12:30 pm **Keynote Speaker: "Landscape and Chronology of Melanoma Metastasis"** - Roger Lo, MD, PhD

12:30 - 1:00 pm **Liaison Updates**

Updates from Adolescent and Young Adult Committee
 Leah Winer, MD

Updates from Prevention Committee - Soo Park, MD

Developing Studies

S2601, "Multicenter Selective Lymphadenectomy Trial – III: A randomized phase 3 noninferiority trial of selective lymphadenectomy of index lymph nodes vs. full therapeutic lymphadenectomy in patients with stage III melanoma achieving major pathologic response to neoadjuvant immunotherapy". Dr. Faries

S2616, "A randomized phase 3 study of anti-PD1, retifanlimab, vs. standard of care observation in patients with subclinical Merkel Cell Carcinoma as evidenced by positive ctDNA after curative-intent treatment with no clinical evidence of disease; the TOMMORRoW trial; Treatment on Merkel MOlecular RecurRence Without clinically evident disease". Dr. Nghiem

S2617, "PRIMER: Phase III Trial of Botensilimab and Pembrolizumab in Resectable Melanoma". Dr. Sharon

Closed Studies

A091903, "A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma. SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022. Temporarily Closed to Accrual as of 10/10/2023. Registration to Arm 3 is Temporarily Closed to Accrual as of 06/16/2025. Closed to Accrual as of 06/04/2026

CTSU/EA6141, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 09/10/2015. Closed to accrual as of 1/8/2026.

S2015, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 04/08/22. Closed to accrual as of 8/28/2025.

Melanoma Committee

CTSU/EA6192, "The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated: 10/23/2020. Closed to accrual as of 9/3/2025.

CTSU/EA6174, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/01/2018. Closed to Accrual as of 07/01/2024.

S2000, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 09/23/2020. Closed: 6/18/2024

S1801, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/06/18. Closed: 05/05/2022.

S1512, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 06/04/2021.

S1607, "A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

S1616, "A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent." Dr. VanderWalde. Activated: 07/17/2017. Closed: 07/15/2020.

S1404, "A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma." Dr. Patel. Activated: 10/15/2015. Closed: 11/02/2017.

CTSU/EA6134, "DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial." SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

CTSU/EA6183, A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D). SWOG Champion: C. D. Lao, MD, MPh Activated: 02/18/2020. Closed: 09/23/2022.

Publications

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S1616 Cellular Neighborhoods Govern Antitumor T-Cell Infiltration Following Anti-CTLA-4 in Melanoma with Primary Resistance to Anti-PD-1. Campbell KM, Chen DG, Bustami ZE, Naser Al Deen NN, Medina E, Gonzalez CR, Maxey J, Thompson MA, Samorodnitsky S, Kuklinski LF, Perez Garcilazo IP, Baselga-Carretero I, Vega-Crespo A, Chen JM, Elumalai R, Visitacion M, Schiemann R, Padron L, Chang C, Zelin AE, Chelluri SS, Boffo S, Kendra KL, Chmielowski B, Truong TG, Khushalani NI, Collichio F, Ikeguchi A, Victor AI, Margolin K, Johnson DB, Chen Y, Sosman JA, Patel SP, Hu-Lieskovan S, Moon J, Wells DK, Spencer CN, Bellasea S, Vanderwalde AM, Wu M, Scumpia PO, Ribas A. *Cancer Discovery*. 2026. <https://pubmed.ncbi.nlm.nih.gov/42013417/>

Submitted Manuscripts

S1512/S1616 Desmoplastic Melanoma Spatial Atlas Reveals Programs of Immunotherapy Response. Daniel G, Truong A, Naser Al Deen N, Gonzalez CR, Medina E, Baselga Carretero I, Chen JM, Kuklinski LF, Eroglu Z, Hu-Lieskovan S, Chmielowski B, Truong TG, Khushalani NI, Ikeguchi AP, Victor AI, Margolin K, Johnson DB, Chen Y, Sosman JA, Carson WE III, In G K, Hyngstrom J, Brohl AS, Wada DA, Plaza JA, Sharon E, Patel SP, Sondak VK, Bellasea SL, Kendra KL, Vanderwalde A, Wu MC, Ribas A, Scumpia PO, Campbell KM. Submitted 2026.

Melanoma Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	<i>S2015</i>	<i>A091903</i>	<i>EA6141</i>	<i>EA6192</i>	<i>EA6194</i>
Banner MD Anderson Cancer Center	39	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	112	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	1	-	-
Cedars-Sinai Medical Center	30	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	3	-	-
Columbia University NCI Community Oncology Research Program	9	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	2	-	-
Duke University - Duke Cancer Institute LAPS	20	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	15	-	-	-	-
Georgia NCI Community Oncology Research Program	11	-	-	-	-
Intermountain Medical Center	44	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	6	-	31	-	-
Medical University of South Carolina NCORP Community Site	20	-	-	-	-
Moffitt Cancer Center	58	-	-	-	-
Northwell Health NCORP	10	-	-	-	-
Northwestern University LAPS	46	-	1	5	-
Ohio State University Comprehensive Cancer Center LAPS	36	-	-	3	-
Regents of the University of Michigan	26	-	1	-	-
Sutter Cancer Research Consortium	-	-	7	-	-
The NCI Community Oncology Research Program: The New Mexico NCORP	7	-	-	-	-
The University of Kansas Cancer Centers- MCA Rural NCORP	48	-	3	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	18	-	4	-	3
USC Norris Comprehensive Cancer Center LAPS	5	1	-	-	-
University of Arizona LAPS	-	-	-	1	1
University of Arkansas for Medical Sciences	7	-	-	1	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	2	-	-
University of Kentucky/Markey Cancer Center	13	-	-	-	-
University of Nebraska Medical Center	4	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	-	-	-
University of Rochester LAPS	7	-	13	-	-
University of Texas Health Science Center at San Antonio	3	-	1	-	-
University of Texas MD Anderson Cancer Center LAPS	23	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	33	-	-	-	-
Western States Cancer Research NCORP	-	-	1	-	-
Wisconsin NCI Community Oncology Research Program	16	-	-	-	-
Yale University - Yale Cancer Center LAPS	29	-	8	-	-
ALLIANCE	132	-	-	-	-
ECOG-ACRIN	228	-	-	-	-
NRG	102	-	-	-	-
Total	1,158	1	78	10	4

